Argenx.
company in Ghent, Belgium
- Reports this week
- 0
- Active events
- 0
- Connections
- 44
What's happening
Earlier this month
One to three months ago
-
Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.Some support2 reports
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.Some support1 report
-
Argenx's drug Vyvgart showed promise in treating various inflammatory diseases.Some support2 reports
-
UBS issued a bullish note on August 26, 2026, which drove up Argenx's stock price.Some support1 report
-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Argenx announced a definitive agreement to acquire Forte Biosciences.Well supported14 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Argenx this week
News at the entities that move Argenx most-
UBS OperationalUBS analysts project upside for Teradyne, which is involved in the testing and supply chain of companies like Nvidia.Moves Argenx
-
University of Pittsburgh OperationalHamas attacks prompted a discussion regarding antisemitism on the campus of the University of Pittsburgh.Moves Argenx
-
Goldman Sachs International TransactionalGoldman Sachs International conducted a share purchase on the LSE involving ExxonMobil, with FCA approval.Moves Argenx
-
Wells Fargo Mentioned togetherAI deepfake video impersonates celebrity Jaden Smith.Moves Argenx
-
Reuters TransactionalReuters reported on the debut of new Exchange Traded Funds (ETFs) linked to Artificial Intelligence.Moves Argenx
-
Netherlands Shared contextAhmed Nasser was arrested by Dutch authorities, leading the Netherlands to close its embassy in Cairo amid protests.Moves Argenx
Connections
The 10 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Forte Transactional
Argenx is acquiring Forte, leading to a merger of Forte into Argenx.
-
Alexandra Roy Structural
Alexandra Roy holds the formal role of Investor Contact for Argenx.
-
University of Pittsburgh Operational
The company utilizes the university for ongoing research collaboration.
-
Rohit Aggarwal Operational
Dr Aggarwal functions as an investigator for a Phase III clinical trial associated with Argenx.
-
Reuters Transactional
Argenx's CFO provided market status commentary to Reuters.
-
UBS Operational
UBS issues market notes and predictions that directly influence Argenx's stock price and market perception.
-
Goldman Sachs International Transactional
Goldman Sachs International acted as the exclusive financial adviser for Argenx regarding an acquisition.
-
Wells Fargo Mentioned together
Wells Fargo analysts provide market predictions and commentary regarding Argenx's share price.
Show all 10 connections
-
Netherlands Shared context
Argenx conducts its operations and announcements within the Netherlands.
-
Teva Pharmaceutical Industries Ltd. Operational
Both companies are actively competing in the market by developing drug prospects against celiac disease.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.
August 2026
2 eventsShow 2 earlier months
June 2026
3 events- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Argenx SE formed a strategic alliance with Unnatural Products Inc. and expanded its therapies across several countries.
- Investor interest in the healthcare AI sector is rising, with future viability depending on Phase 3 trial outcomes.